Dianthus Therapeutics Inc <DNTH.O>: Truist Securities Raises Target Price to $128 From $110
DNTH•Related News
Collegium turns to GAAP net loss of $15.1 million in Q2 FY26; revenue rises 6% to $199.9 million
COLL•
Netscout Q1 revenue beats expectations on service assurance orders growth
NTCT•
Dynatrace, Inc <DT.N>: Rosenblatt Securities raises target price to $62 from $52
DT•
Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs
CMPX•
Ironwood Q2 revenue rises 33%
IRWD•